These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. A retrospective case-control analysis of the efficacy of Gardasil Milner TD; Harrison A; Montgomery J; MacGregor FB; Buchanan MA; MacKenzie K Clin Otolaryngol; 2018 Jun; 43(3):962-965. PubMed ID: 29380936 [No Abstract] [Full Text] [Related]
29. Characterization of serum antibodies from women immunized with Gardasil: A study of HPV-18 infection of primary human keratinocytes. Wang HK; Wei Q; Moldoveanu Z; Huh WK; Vu HL; Broker TR; Mestecky J; Chow LT Vaccine; 2016 Jun; 34(27):3171-3177. PubMed ID: 27113165 [TBL] [Abstract][Full Text] [Related]
30. Gardasil-9: A global survey of projected efficacy. Zhai L; Tumban E Antiviral Res; 2016 Jun; 130():101-9. PubMed ID: 27040313 [TBL] [Abstract][Full Text] [Related]
31. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565 [TBL] [Abstract][Full Text] [Related]
33. Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation. Insinga RP; Dasbach EJ; Allen SE; Carides GW; Myers ER Value Health; 2008 Dec; 11(7):1022-32. PubMed ID: 18489503 [TBL] [Abstract][Full Text] [Related]
34. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. Petrosky E; Bocchini JA; Hariri S; Chesson H; Curtis CR; Saraiya M; Unger ER; Markowitz LE; MMWR Morb Mortal Wkly Rep; 2015 Mar; 64(11):300-4. PubMed ID: 25811679 [TBL] [Abstract][Full Text] [Related]
35. Clearance of recalcitrant warts in a patient with idiopathic immune deficiency following administration of the quadrivalent human papillomavirus vaccine. Smith SP; Baxendale HE; Sterling JC Clin Exp Dermatol; 2017 Apr; 42(3):306-308. PubMed ID: 28070898 [TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and safety of quadrivalent human papillomavirus types 6/11/16/18 recombinant vaccine in chronic kidney disease stage IV, V and VD. Praditpornsilpa K; Kingwatanakul P; Deekajorndej T; Rianthavorn P; Susantitaphong P; Katavetin P; Tiranathanakul K; Srisawat N; Tungsanga K; Eiam-Ong S; Townamchai N Nephrol Dial Transplant; 2017 Jan; 32(1):132-136. PubMed ID: 26932687 [TBL] [Abstract][Full Text] [Related]
37. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain. Navarro-Illana E; López-Lacort M; Navarro-Illana P; Vilata JJ; Diez-Domingo J Vaccine; 2017 Jun; 35(25):3342-3346. PubMed ID: 28499554 [TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM). Hidalgo-Tenorio C; Ramírez-Taboada J; Gil-Anguita C; Esquivias J; Omar-Mohamed-Balgahata M; SamPedro A; Lopez-Ruz M; Pasquau J AIDS Res Ther; 2017 Jul; 14(1):34. PubMed ID: 28720147 [TBL] [Abstract][Full Text] [Related]
40. A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18. Goldstone SE; Vuocolo S Expert Rev Vaccines; 2012 Apr; 11(4):395-406. PubMed ID: 22551023 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]